PROGESTERONE AND PROGESTATIONAL COMPOUNDS IN THE TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA

1965 ◽  
Vol 49 (3) ◽  
pp. 412-426 ◽  
Author(s):  
Per Bergsjö
Keyword(s):  
Endometrial Carcinoma ◽  
Lung Metastases ◽  
Endometrial Adenocarcinoma ◽  
Cervical Adenocarcinoma ◽  
Tumour Tissue ◽  
Pelvic Tumour ◽  
Histological Alterations

ABSTRACT Various doses of progesterone in oil and of two progestational compounds (17α-hydroxy-19-nor-progesterone caproate and 17α-hydroxyprogesterone p-butoxyphenyl propionate) have been given to 15 patients with recurrent and/or metastatic endometrial adenocarcinoma and to one patient with metastatic cervical adenocarcinoma, for periods of up to 27 weeks. Regression of lung metastases was noted in 4 of 13 patients, softening of pelvic tumour in 2 of 4, and histological alterations of tumour tissue in 4 of 5 patients. In the patient with metastases from a cervical adenocarcinoma, the disease progressed during the treatment. The significance of the observations is discussed.

Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17111-e17111 ◽  
Author(s):  
Sumita Trivedi ◽  
Felicia Williams ◽  
William L. Read
Keyword(s):  
Endometrial Cancer ◽  
Weight Gain ◽  
Endometrial Carcinoma ◽  
Lung Metastases ◽  
Performance Status ◽  
Endometrial Adenocarcinoma ◽  
Case Series ◽  
Poor Performance Status ◽  
Second Primary ◽  
Lung Lesions

e17111 Background: Megestrol (M) is an effective palliative treatment for endometrial carcinoma but causes weight gain via activity at the corticosteroid receptor. Norethindrone (N) is a progestin without corticosteroid activity. We report 3 women with metastatic endometrial cancer responsive to M for whom a switch to N decreased side effects with continued cancer control. Methods: Case-series Results: 1. 62 year old with endometrial adenocarcinoma underwent surgery and chemoradiation. Lung metastases were discovered 31 months later and she began M with complete response at 13 months. She suffered weight gain and lymphedema. M was switched to N and continued for 4 years to date with weight loss and without progression. 2. 54 year old with endometrial adenocarcinoma underwent surgery and radiation. Lung metastases developed 30 months later. Chemotherapy produced response but was complicated by cerebrovascular accident. lung lesions developed 3 years later and slowly grew over the ensuing year. M was started and continued for 8 months. Her lung lesions responded but weight gain impacted her already reduced mobility. She was switched to N which has continued 11 months to date, with stable disease, without further weight gain. 3. 64 year old with a history of metastatic squamous cell carcinoma of the lung developed what was thought to be a second primary endometrial adenocarcinoma. She received surgery and radiation with pelvic recurrence 34 months later. M was started and continued for 17 months with response in pelvic and lung lesions, which proved to be metastatic endometrial carcinoma presenting before her primary. Weight gain resulted in wheelchair dependence. She was switched to N with continuing response over the ensuing 2 years. 28 months after starting N, imaging showed progression and she was switched back to M, her poor performance status precluding other treatments. She died 5 months later. Conclusions: In patients with metastatic endometrial cancer responding to megestrol, switching to norethindrone improved palliative benefit. Prospective clinical trials of norethindrone or similar progestins without corticosteroid activity should be considered for this population.

Immunocytochemical localization of β1-4 galactosyltransferase in endometrial carcinoma cells

1990 ◽  
Vol 48 (3) ◽  
pp. 944-945
Author(s):  
Ichiro Yamamoto ◽  
Toshiaki Tachibana ◽  
Hiroko Maruyama ◽  
Noriyuki Komatsu ◽  
Hiroyuki Kuramoto ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Cell Lines ◽  
Endometrial Adenocarcinoma ◽  
Protein A ◽  
Rabbit Antiserum ◽  
Carcinoma Cells ◽  
Affinity Column ◽  
Antibody Technique ◽  
Galactosyl Transferase ◽  
C Terminus

We have paid attention to the alteration of glycosyltransferase in carcinoma cells, because it might be related to the malignancy of the cells. In this connection, localization of β1-4 galactosyl transferase (β1-4 Gal T) in human endometrial carcinoma cells was examined immunocytochemically using two kinds of cell lines, each of which showed different degree of differentiation.An antibody was purified from the rabbit antiserum against the synthetic peptide, IFNRLVFRGMSC (W89) of human β1-4 Gal T coupled with KLH (keyhole limpet hemocyanine) by protein A column and peptide-affinity column chromatography. The anti-W89 serum reacts to the C-terminus of human β 1-4 Gal T and to both membrane-bound and soluble forms of the enzyme. Cell line of well differentiated endometrial adenocarcinoma (I) and that of poorly differentiated endometrial adenocarcinoma (50B) were cultivated respectively in MEM medium containing 15% FCS and 2 mM glutamine for 4 d at 37°C under 5% CO2. The cells were fixed in a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M Soerensen’s phosphate buffer (pH 7.4) at 4°C for 30 min, washed with PBS, then freezed and thawed. The indirect method of the peroxidase- labeled antibody technique was used for immunocytochemistry of both LM and TEM on the cell lines. The cells were dehydrated in ethanol and embedded in TAAB 812. Ultrathin sections were observed under a TEM, JEM-100S.

scholarly journals p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy

2003 ◽  
Vol 121 (4) ◽  
pp. 163-166 ◽  
Author(s):  
Vera Lúcia Leite Bonfitto ◽  
Liliana Aparecida Lucci de Angelo Andrade
Keyword(s):  
Endometrial Carcinoma ◽  
Histological Grade ◽  
Endometrial Adenocarcinoma ◽  
Progesterone Receptors ◽  
Histological Type ◽  
Morphological Data ◽  
Disease Stage ◽  
Biological Behavior ◽  
Endometrioid Carcinoma ◽  
Estrogen And Progesterone Receptors

CONTEXT: Diagnostic staging is an important prognostic factor for endometrial adenocarcinoma. Apart from the histological type and histological grade, some markers seem to be associated with the stage and biological behavior of the disease. Among these are p53, estrogen and progesterone receptors. OBJECTIVE: The objectives of the present study were: to compare histological type and grading of endometrial carcinoma in curettage and hysterectomy samples; to assess expression of p53, estrogen and progesterone receptors in curettage specimens; and to correlate these data with morphology and staging of the disease in hysterectomy specimens. TYPE OF STUDY: Retrospective. SETTING: Department of Pathology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas. SAMPLE: Histological diagnosis from 51 consecutive files. PROCEDURES: Immunohistochemical reactions for p53, estrogen and progesterone receptors via the avidin-biotin-peroxidase method in 51 curettage samples endometrial carcinoma were compared with the morphological data and disease stage in hysterectomy. Marker expression was correlated with histological type and grade and the final stage of the disease. RESULTS: According to the histological type: 44 cases (86%) were of endometrioid and 7 (14%) non-endometrioid carcinoma. p53 expression was observed in 16% of endometrioid and 71% of non-endometrioid cases (p < 0.05). Although estrogen expression was more evident in endometrioid (54%) than non-endometrioid cases (29%), this was not statistically significant. Progesterone receptor expression was significantly higher in endometrioid than non-endometrioid cases (70% vs. 14%, p < 0.05). According to the histological grade: Estrogen and progesterone receptors were expressed more frequently in grade I endometrioid carcinoma, while p53 was mainly reported in tumor grades II and III. According to final disease stage: p53 and estrogen expression in curettage specimens was not related to stage; progesterone receptors, however, were expressed significantly less in advanced disease. CONCLUSION: p53 was observed in the majority of non-endometrioid and in high-grade endometrioid carcinoma, but was not related to stage. Estrogen and progesterone receptors were mainly found in grade I endometrioid carcinoma. The markers studied in curettage were no more valuable for predicting the disease stage than classical histological criteria.

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.

1994 ◽  
Vol 12 (7) ◽  
pp. 1408-1414 ◽  
Author(s):  
J T Thigpen ◽  
J A Blessing ◽  
P J DiSaia ◽  
E Yordan ◽  
L F Carson ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Stable Disease ◽  
Lung Metastases ◽  
Gynecologic Oncology ◽  
Survival Duration ◽  
Poor Performance Status ◽  
Combination Regimen ◽  
Gynecologic Oncology Group ◽  
Prognostic Features ◽  
Prior Therapy

PURPOSE From 1979 to 1984, 356 eligible patients with advanced or recurrent endometrial carcinoma no longer amenable to therapy with surgery, radiotherapy, or progestins were treated with doxorubicin alone or doxorubicin in combination with cyclophosphamide. PATIENTS AND METHODS Patients were randomized to receive doxorubicin 60 mg/m2 intravenously (i.v.) with or without cyclophosphamide 500 mg/m2 i.v. every 3 weeks for eight drug courses. All patients had received prior therapy with progestins with subsequent progression of disease. No patients had received prior therapy with cytotoxic drugs. Of 356 patients, 300 had measurable disease. RESULTS Among 132 patients treated with doxorubicin alone, there were seven complete responses (5%), 22 partial responses (17%), 73 with stable disease (55%), and 30 with increasing disease within 2 months of study entry (23%). For the 144 patients who received the combination, there were 18 complete responses (13%), 25 partial responses (17%), 75 with stable disease (52%), and 26 with increasing disease (18%). The median progression-free interval for those patients who received doxorubicin alone was 3.2 months, while it was 3.9 months for those who received the combination. The median survival duration for doxorubicin patients was 6.7 months, while it was 7.3 months for the combination patients. None of the unadjusted estimates of treatment differences are statistically significant. Prognostic features that had an impact on outcome included one factor associated with an increased likelihood of response (presence of measurable lung metastases) and four features associated with a poorer survival (poor performance status [PS] of 2 or 3, high pathologic grade, and presence of liver metastases or other intraabdominal disease). If these features are taken into account in multivariate analyses, there is no statistically significant evidence for differences in response rates (relative odds of response, 1.58; P = .06, one-tailed test), and survival duration is slightly longer in the combination regimen (17% reduction in death rate; P = .048). CONCLUSION The combination of doxorubicin plus cyclophosphamide thus appears to offer a small advantage over doxorubicin alone in the management of endometrial carcinoma at the expense of more frequent and severe myelosuppression and gastrointestinal toxicity.

scholarly journals Forgotten Lippes Loop associated with Endometrial Carcinoma

2011 ◽  
Vol 3 (3) ◽  
pp. 147-148
Author(s):  
Smiti Nanda ◽  
Savita Rani Singhal ◽  
Seema Madan
Keyword(s):  
Endometrial Carcinoma ◽  
Vaginal Bleeding ◽  
Intrauterine Device ◽  
Endometrial Adenocarcinoma ◽  
Postmenopausal Bleeding ◽  
Endometrial Sampling

ABSTRACT Patients with a forgotten intrauterine device (IUD) present most often with irregular vaginal bleeding or postmenopausal bleeding. We report a case of nonmedicated IUD (Lippes loop) associated with endometrial adenocarcinoma in a woman who presented with postmenopausal bleeding and a forgotten IUD. Although the occurrence of endometrial adenocarcinoma with IUD is almost unknown, yet given the serious nature of the disease, endometrial sampling is indicated in any patient with postmenopausal bleeding and IUD in situ.

scholarly journals Endometrial carcinoma metastatic to the scalp

2021 ◽  
Vol 54 (2) ◽  
Author(s):  
Joana Aidos ◽  
Sónia Gonçalves ◽  
Teresa Carvalho ◽  
Nuno Nogueira Martins ◽  
Francisco Nogueira Martins
Keyword(s):  
Endometrial Carcinoma ◽  
Endometrial Adenocarcinoma ◽  
Cutaneous Metastasis ◽  
Scalp Metastasis ◽  
Widespread Dissemination

Endometrial carcinoma is a very rare cause of cutaneous metastasis. The most frequent presentations of cutaneous metastasis are fast developing nodules or tumors, which are evidence of widespread dissemination in such patients. We report a case of scalp metastasis from an endometrial adenocarcinoma with a fatal prognosis.  

Clear Cell Carcinoma of Endometrium

1979 ◽  
Vol 65 (2) ◽  
pp. 201-205 ◽  
Author(s):  
Silvestro G. Carinelli ◽  
Francomaria Senzani
Keyword(s):  
Cell Carcinoma ◽  
Endometrial Carcinoma ◽  
Sex Hormones ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Endometrial Adenocarcinoma

Three cases of clear cell carcinoma of the endometrium are here reported. Clear cell carcinoma is a rare and aggressive type of endometrial adenocarcinoma. Patients are older and are in the menopause much longer than are patients with typical endometrial carcinoma. This fact may reflect the presence of counterbalanced sex hormones in the process of carcinogenesis.

Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5533-5533
Author(s):  
J. Qian ◽  
D. Weber ◽  
R. Cochran ◽  
D. Hossain ◽  
D. G. Bostwick
Keyword(s):  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Endometrial Carcinoma ◽  
Endometrial Adenocarcinoma ◽  
Atypical Hyperplasia ◽  
Chromosome 1 ◽  
Chromosomal Anomalies ◽  
Tissue Samples ◽  
Gynecological Malignancy

5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy. The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging. We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH). Methods: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol. For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers. Each was hybridized using fluorescence labeled DNA probes to chromosomes 1, 8, and 10 (UteroFISH). The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples. Results: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens. The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001). The most frequent chromosomal anomaly was gain of chromosome 1. FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma. There was no association with grade of endometrial carcinoma. Conclusions: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity. Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document